Literature DB >> 15161462

Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study.

Mauro Di Bari1, Lonneke V van de Poll-Franse, Graziano Onder, Stephen B Kritchevsky, Anne Newman, Tamara B Harris, Jeff D Williamson, Niccoló Marchionni, Marco Pahor.   

Abstract

OBJECTIVES: To evaluate whether older persons using angiotensin-converting enzyme (ACE) inhibitors have a larger lower extremity muscle mass (LEMM) than users of other antihypertensive drugs.
DESIGN: Cross-sectional analysis of data from the Health, Aging and Body Composition (Health ABC) Study.
SETTING: University of Tennessee, Memphis, and University of Pittsburgh clinics. PARTICIPANTS: A community-based sample of 2,431 well functioning participants of the Health ABC, aged 70 to 79, who were free of heart failure, were selected according to use of antihypertensive medications: ACE inhibitors (n=197), beta-blockers (n=169), thiazides (n=216), calcium-channel blockers (n=340), or none (n=1,509). MEASUREMENTS: LEMM, assessed using dual-energy x-ray absorptiometry, compared by index drug in analysis of variance models unadjusted and adjusted for demographics, study site, height, body fat, physical activity, blood pressure, coronary artery disease, diabetes mellitus, and chronic pulmonary disease.
RESULTS: LEMM significantly differed across the study groups, being larger in users of ACE inhibitors than in users of other drugs (unadjusted and adjusted models). LEMM was comparable in users of ACE inhibitors and no drug users. A trend toward larger LEMM was also observed in sex- and ethnicity-stratified analyses and in the subgroup of noncoronary hypertensive participants.
CONCLUSION: In older persons, use of ACE inhibitors is associated cross-sectionally with larger LEMM. This finding suggests a possible explanation of the benefits of ACE inhibitors in wasting syndromes. If confirmed in longitudinal studies, this pharmacological action might have important implications for the prevention of physical disability in older patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161462     DOI: 10.1111/j.1532-5415.2004.52265.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  58 in total

1.  Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction.

Authors:  Christy S Carter; Leanne Groban
Journal:  Aging health       Date:  2008-02-01

2.  Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise.

Authors:  Thomas W Buford; Todd M Manini; Fang-Chi Hsu; Matteo Cesari; Stephen D Anton; Susan Nayfield; Randall S Stafford; Timothy S Church; Marco Pahor; Christy S Carter
Journal:  J Am Geriatr Soc       Date:  2012-06-21       Impact factor: 5.562

Review 3.  Successful aging: Advancing the science of physical independence in older adults.

Authors:  Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor
Journal:  Ageing Res Rev       Date:  2015-10-14       Impact factor: 10.895

Review 4.  Ace inhibitors as a therapy for sarcopenia - evidence and possible mechanisms.

Authors:  D Sumukadas; M D Witham; A D Struthers; M E T McMurdo
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

5.  HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.

Authors:  Kimberly M Demos-Davies; Bradley S Ferguson; Maria A Cavasin; Jennifer H Mahaffey; Sarah M Williams; Jessica I Spiltoir; Katherine B Schuetze; Todd R Horn; Bo Chen; Claudia Ferrara; Beatrice Scellini; Nicoletta Piroddi; Chiara Tesi; Corrado Poggesi; Mark Y Jeong; Timothy A McKinsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

6.  Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IlSIRENTE study.

Authors:  Graziano Onder; Rosa Liperoti; Andrea Russo; Ettore Capoluongo; Angelo Minucci; Paola Lulli; Matteo Cesari; Marcello Maggio; Roberto Bernabei; Francesco Landi
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 7.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

8.  Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II).

Authors:  Dominik Spira; Jeremy Walston; Nikolaus Buchmann; Jivko Nikolov; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Rahel Eckardt; Kristina Norman
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

Review 9.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

Review 10.  Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis.

Authors:  Ling-shan Zhou; Ling-jie Xu; Xue-qing Wang; Yi-huan Huang; Qian Xiao
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.